Incyte To Highlight New, Late-Breaking 54-Week Data For Povorcitinib In Hidradenitis Suppurativa At 2026 AAD Annual Meeting

Incyte (NASDAQ: INCY) will present new, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa at the 2026 American Academy of Dermatology Annual Meeting scheduled for March 27 – 31, 2026, in Denver. The presentation will also feature abstracts for ruxolitinib cream (Opzelura®) and povorcitinib, including multiple ePosters on atopic dermatitis, hidradenitis suppurativa, and vitiligo.